Want to see AU:CYP full AI Analyst Report?
CYP Stock Chart & Stats
AU$0.29
-AU$0.01(-4.17%)
At close: 4:00 PM EST
AU$0.29
-AU$0.01(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.44
Previous CloseN/A
Volume63.41K
Average Volume (3M)233.82K
Market Cap
AU$3.41M
Enterprise ValueAU$60.71M
Total Cash (Recent Filing)AU$5.05M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding243,454,380
10 Day Avg. Volume170,513
30 Day Avg. Volume233,823
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)5.14
Price to Sales (P/S)16.31
P/FCF Ratio-3.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)AU$19.90M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt is a durable financial strength for a clinical-stage biotech: it reduces refinancing and interest burdens, preserves flexibility to prioritize R&D or partnerships, and lengthens runway options when raising equity or pursuing non-dilutive funding over the next 2–6 months.
Scalable IPSC‑derived MSC PlatformA scalable allogeneic iPSC‑derived MSC platform is a structural competitive advantage: it targets off‑the‑shelf manufacturing consistency and scale, which can lower per‑unit costs and enable broader commercial reach versus autologous models if clinical programs succeed.
High Gross Margin PotentialVery high reported gross margins suggest favorable unit economics once products commercialize: low variable costs per unit can translate into rapid operating leverage as revenue scales, improving sustainability of profits over the medium term if fixed R&D overhead is controlled.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow is a durable weakness: the company relies on external funding to progress trials, raising dilution and execution risk. Continued cash burn constrains simultaneous development programs and limits strategic optionality over months.
Very Large Operating LossesDeep negative net margins and recurring operating losses indicate the business is not near profitability; this structural loss profile implies material future capital needs, increases dependency on financings or partnerships, and raises execution risk for achieving commercial breakeven.
Declining Equity And Total AssetsMaterial declines in equity and total assets reduce financial buffers and suggest reserve depletion from funding operations. This weakens balance sheet resilience to setbacks, limits borrowing or partnership leverage, and heightens medium‑term solvency and dilution risks.
Cynata Therapeutics Limited News
CYP FAQ
What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest share price was AU$0.01 and its highest was AU$0.43 in the past 12 months.
What is Cynata Therapeutics Limited’s market cap?
Cynata Therapeutics Limited’s market cap is AU$3.41M.
When is Cynata Therapeutics Limited’s upcoming earnings report date?
Cynata Therapeutics Limited’s upcoming earnings report date is Aug 31, 2026 which is in 61 days.
How were Cynata Therapeutics Limited’s earnings last quarter?
Cynata Therapeutics Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is Cynata Therapeutics Limited overvalued?
According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued.
Does Cynata Therapeutics Limited pay dividends?
Cynata Therapeutics Limited does not currently pay dividends.
What is Cynata Therapeutics Limited’s EPS estimate?
Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cynata Therapeutics Limited have?
Cynata Therapeutics Limited has 243,454,380 shares outstanding.
What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
Cynata Therapeutics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.054%.
Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:CYP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cynata Therapeutics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYP Sentiment 73%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
-179.37%
Trailing 12-Months
Asset Growth
-62.21%
Trailing 12-Months
Company Description
Cynata Therapeutics Limited
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
Technical Analysis
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―